blue cross blue shield reverse course on glp 1 Why is rolling back coverage of GLP-1 weight loss drugs in Massachusetts Medicare Bridge Program Explained: GLP-1

A vehicle-free antimicrobial polymer hybrid gold nanoparticle as synergistically therapeutic platforms for Staphylococcus aureus infected wound healing

More about the management of these shortages For the past 2 years, EMA and the EU regulatory network have been closely monitoring these shortages through the Medicine Shortages SPOC WP and the MSSG

By inhibiting this pathway, epalrestat improves metabolic imbalances associated with DN

Biotechnology Journal 18: 2200398 (2023) Karunarathna I, Bandara S, Jayawardana A, de Alvis K, Gunasena P, Hapuarachchi T, Ekanayake U, Rajapaksha S, Gunawardana K, Aluthge P, Gunathilake S

They can promote positive changes in the microbiome, helping feed beneficial gut microbes, for example, which produce anti-inflammatory short-chain fatty acids

Then the dominoes: the LIFT-AD trial failed in September 2024, the Department of Justice settlement landed in January 2025, and the formal retractions of two foundational papers followed in April 2025